CN Patent

CN112500358B — 赛乐西帕晶型及其制备方法

Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2022-03-15 · 4y expired

What this patent protects

本发明涉及具有改善性质的赛乐西帕新晶型及其制备方法，该方法采用循环析晶的方式得到一种赛乐西帕晶型A。与传统赛乐西帕晶型相比，该赛乐西帕晶型A的熔点高，稳定性好，晶型纯度高，有关物质含量低，工艺条件温和，适合大规模生产，包含该晶型的药物组合物及剂型可用于治疗肺动脉高压疾病。

USPTO Abstract

本发明涉及具有改善性质的赛乐西帕新晶型及其制备方法，该方法采用循环析晶的方式得到一种赛乐西帕晶型A。与传统赛乐西帕晶型相比，该赛乐西帕晶型A的熔点高，稳定性好，晶型纯度高，有关物质含量低，工艺条件温和，适合大规模生产，包含该晶型的药物组合物及剂型可用于治疗肺动脉高压疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN112500358B
Jurisdiction
CN
Classification
—
Expires
2022-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.